Pradaxa (dabigatran etexilate) is a drug in a new generation of direct oral anticoagulants designed to target acute and chronic thromboembolic diseases.
Pradaxa (dabigatran etexilate) was the first widely approved drug in a new generation of direct oral anticoagulants designed to target a high unmet medical need in the prevention and treatment of acute and chronic thromboembolic diseases. Potent antithrombotic effects are achieved with direct thrombin inhibitors by specifically blocking the activity of thrombin, the central enzyme in the process responsible for clot (thrombus) formation.
Currently approved indications for Pradaxa are prevention of a stroke and systemic embolism in patients with non-valvular atrial fibrillation and prevention of venous thromboembolic events in patients undergoing elective total hip replacement surgery and elective total knee replacement.
In November 2013, Boehringer Ingelheim announced the upcoming presentation of the latest efficacy and safety data for Pradaxa at the 2013 American Heart Association’s Scientific Sessions.